Sporevia™ (Bacillus subtilis ATCC122264) is a spore-forming probiotic that offers signature durability  across a wide range of supplement applications and formats.

Scientific research supports the safety and viability of the strain.

This stable spore-forming probiotic can survive harsh manufacturing processes such as shear, HTST and HPP pasteurisation as well as the journey through the digestive system. It is easy to formulate into functional foods, beverages, supplements and companion animal products without changes to composition or taste.

Sporevia is Kosher + Halal certified. It is not formulated with any allergens, gluten, animal products, or genetically-modified ingredients. It possesses an extended shelf-life up to 30 months.

Download The Sporevia™ Product Information Sheet

The Research

A clinical trial has found that Kerry Group’s probiotic strain Sporevia (Bacillus subtilis MB40) can eliminate Staphylococcus aureus in the human body by more than 95%. Sporevia is a probiotic strain owned by Kerry Group following the licensing agreement with the company BIO-CAT Microbials in June 2021.

According to a 2019 CDC report, ‘staph’ (Staphylococcus aureus), is a pathogen that caused over 119,000 infections and nearly 20,000 deaths in the US in 2017.1 However, the use of oral antibiotics for staph decolonisation isn’t recommended because of its effect on the gut microbiota and antibiotic resistance.

Following the discovery that Sporevia secretes fengycin, which has been shown to inhibit S. aureus colonisation, the double-blind, randomized, placebo-controlled trial was conducted .

One hundred and fifteen adults from Thailand took part in the study, which was funded by the US National Institutes of Health and the National Research Council of Thailand. All were colonised by S. aureus, either in the intestine, nose, or both, but had no history of intestinal disease, antibiotic treatment, or hospital admission within the previous 90 days.

Receiving either 250 mg of Sporevia* (10 billion CFU) or placebo once a day for 30 days, S. aureus colonisation was determined. Oral supplementation with Sporevia resulted in a 96.8% reduction of S. aureus in the stool and a 65.4% reduction of S. aureus in the nose. There were no significant differences in the placebo groups.

Bacillus subtilis in a dish

This decolonization was achieved without adverse effects or significant microbiome changes. According to the researchers, the findings indicate potential for Bacillus subtilis to be used to lower infection rates in vulnerable individuals, and in long-term care facilities such as nursing homes.

“We were delighted to have Sporevia selected for this study,” says John Menton, PhD, Senior Product Director, Digestive Health, at Kerry Group. “We have long understood the power of spore-forming probiotics to produce metabolites, enzymes and, depending on the strain, fengycins which may inhibit the growth of deleterious bacteria. In this case the study found that Sporevia produces higher amounts of fengycins than other probiotic strains considered for the study, which made it a great candidate for further research. While we’re not surprised by the conclusions, it’s always great to see hypotheses based on in vitro and animal model data supported by clinical trial results. This study is very encouraging as it demonstrates Sporevia’s potential in bacteria management.”

  • The B. subtilis probiotic formula (Sporevia) was purchased from Kerry Group but the suppliers did not have any influence on the study design or interpretation.

View the full study at: thelancet.com

[1] https://www.cdc.gov/media/releases/2019/p0305-deadly-staph-infections.html